This webinar discusses the FDA's accelerated approval of daratumumab to treat patients with multiple myeloma who have received at least three prior treatments. Daratumumab is the first monoclonal antibody approved for treating multiple myeloma.
Mikkael Sekeres, MD, Director, Leukemia Program, Professor of Medicine, Cleveland Clinic, Cleveland, OH
Nicole Gormley, MD, Acting Clinical Team Lead, Scientific Liaison for Multiple Myeloma, Division of Hematology Products, U.S. Food and Drug Administration, Silver Spring, MD
Paul G. Richardson, MD, RJ Corman Professor of Medicine, Harvard Medical School, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA